The rationale for prophylactic cancer vaccines and need for a paradigm shift.
This review summarizes clinical experience with infectious disease vaccines and data from animal tumor models that support a paradigm shift for cancer vaccines from therapeutic to prevention applications.
Sobol
R E
RE
Sidney Kimmel Cancer Center, Introgen Therapeutics Inc., Houston, TX 77030, USA. r.sobol@introgen.com
D000465:Algorithms; D000818:Animals; D030801:Animals, Genetically Modified; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D006801:Humans; D009369:Neoplasms / Q000517:prevention & control* / Q000628:therapy; D009374:Neoplasms, Experimental / Q000517:prevention & control / Q000628:therapy
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines